Recurrent vaginal candidiasis (RVVC) is a chronic subtype of vaginal candidiasis (VVC) with at least four symptomatic episodes in 12 months. Current estimates indicate that 75% of all women will develop VVC in their lifetime with up to 10% of women experiencing RVVC. They often have monthly symptomatic recurrences despite standard treatment. Thus, many patients receive prolonged fluconazole treatment known as 'maintenance therapy'. Relapse is common after cessation of maintenance therapy, and some require indefinite treatment. Quality of life (QoL) is significantly impacted by unmet treatment needs and subsequent physical and psychological consequences. Identifying potential gaps in RVVC management and improving the quality of life of people with RVVC requires a better understanding of the patient experience. There is a lack of well-researched therapeutic options that can be used in place of standard azole therapy for those who do not want to take pharmaceutical treatments or for whom these treatments are inappropriate e.g. pregnancy, allergic responses, and concomitant disease states. There is no consideration of the potential impacts of azole drugs such as fluconazole on the vaginal and gastrointestinal microbiome when used long-term. This PhD project aimed to explore the clinical management, alternative treatment options and patient perspectives of those living with RVVC. [...]